Bisphosphonates
High-yield Verified · Oct 2026Prototype: alendronate
Bisphosphonates are a class of medications used for postmenopausal, male, and glucocorticoid-induced osteoporosis.
Medical view → mechanisms, drug comparisons and Step 1 pharmacology
Osteoclast inhibitors (stem -dronate). The pharmacology is simple; much of the safety lies in how the tablet is taken.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Bone is constantly rebuilt — and osteoclasts are the demolition crew
Bone looks static but is continuously remodeled: osteoclasts dissolve and remove old bone (resorption), and osteoblasts lay down new bone (formation). Bone mass peaks in the third decade of life, and bone loss begins after that. After menopause (estrogen loss) and with age, the osteoclasts outpace the osteoblasts — resorption exceeds formation, bone becomes porous and thin, and the result is osteoporosis with its fragility fractures of the hip, spine, and wrist. To rebuild density, you have to restrain the demolition crew.
That is exactly what a bisphosphonate does. It binds avidly to the hydroxyapatite mineral of bone, concentrating at sites of active resorption. When an osteoclast chews into that bone, it swallows the drug — and the nitrogen-containing bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) then poison the osteoclast’s mevalonate pathway by blocking farnesyl pyrophosphate synthase, collapsing the cell’s "ruffled border" cytoskeleton and triggering osteoclast apoptosis. With resorption suppressed, formation catches up — bone density rises and fracture risk falls. Because the drug is buried in bone, it has a remarkably long skeletal half-life (years) — the rationale for a later "drug holiday."
02 Why the administration protocol matters
A central fact for nursing care: oral bisphosphonates are barely absorbed — under 1% bioavailability — and that tiny fraction is sharply cut by food, calcium, coffee, juice, or mineral water in the stomach (for alendronate, negligible after breakfast and about 60% lower with coffee or orange juice). Worse, the drug is directly corrosive to the lining of the esophagus: if a tablet lingers there, it can cause esophagitis, ulcers, and even strictures. Both problems have the same solution, which is why the protocol is non-negotiable. Take the tablet first thing in the morning on an empty stomach, swallow it with a full glass (6–8 oz) of plain water only, then stay upright — sitting or standing — for at least 30 minutes (a full 60 minutes for ibandronate) and until after the first food of the day, and wait ≥30 minutes (60 for ibandronate) before eating, drinking anything else, or taking any other medication (including calcium, antacids, and vitamins).
Read the protocol as two goals working together. Plain water on an empty stomach + waiting before food rescues the fragile absorption (nothing there to bind the drug). The full glass of water + staying upright washes the tablet down and keeps it from resting against the esophagus — preventing the corrosive injury. Separating from calcium and antacids matters because calcium, antacids, and other multivalent-cation products interfere with absorption of what little drug would be absorbed. Get the protocol right and the drug works safely; get it wrong and you either waste the dose or burn the esophagus.
03 The serious risks — jaw, femur, calcium, and the IV kidney
Beyond the esophagus, three risks call for teaching and monitoring. Osteonecrosis of the jaw (ONJ) — exposed, non-healing jawbone — is rare with oral osteoporosis doses but rises with IV/high-dose (oncology) use and after invasive dental procedures; the defense is a dental exam before starting and good oral hygiene. Atypical femoral fractures — low-energy breaks of the thigh bone from long-term use — are often heralded by new dull thigh or groin pain, which is the reason to report that symptom and the rationale for considering a drug holiday after 3–5 years in patients at low risk for fracture (the optimal duration is not established). And because bisphosphonates lower serum calcium, any hypocalcemia must be corrected before starting, with adequate calcium and vitamin D throughout.
The IV agents add their own two considerations. Zoledronic acid commonly causes a self-limited acute-phase reaction — flu-like fever, myalgia, and arthralgia in the first few days after an infusion (worst after the first dose, treatable with acetaminophen). More seriously, it is renally cleared and nephrotoxic: the osteoporosis product (Reclast, 5 mg) is contraindicated when creatinine clearance is below 35 mL/min and in acute renal impairment (the oncology dose is not recommended in severe renal impairment), so patients must be well hydrated before the infusion and have renal function and calcium checked. None of these carry a class-wide boxed warning, but each is a specific thing the nurse actively teaches and monitors for.
Drug names
Indications
- Postmenopausal, male, and glucocorticoid-induced osteoporosis
- Paget disease of bone
- Hypercalcemia of malignancy; bone metastases / multiple myeloma (IV agents)
Mechanism of action
Bisphosphonates bind avidly to hydroxyapatite at sites of active bone resorption and are taken up by osteoclasts. Nitrogen-containing agents (alendronate, risedronate, ibandronate, zoledronic acid, pamidronate) inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting the osteoclast cytoskeleton/ruffled border and inducing osteoclast apoptosis. The net effect is decreased bone resorption so that formation predominates, raising bone mineral density and reducing fracture risk; the drug’s long skeletal retention underlies the concept of a drug holiday.
Therapeutic effects — what you'll see working
The goal is stronger bone and fewer fractures over years. Judge success by rising bone mineral density (DEXA T-score), fewer fractures, and — for Paget/hypercalcemia — falling bone-turnover markers and serum calcium. Adherence to the administration protocol is essential for any effect at all.
- ↑ Bone mineral density
- Suppressing resorption lets formation catch up, so BMD rises — tracked by DEXA (T-score) over time. Stable or rising BMD without new fractures is the measure of success.
- Reduced fracture risk
- Denser, stronger bone means fewer fragility fractures of the spine, hip, and other nonvertebral sites (ibandronate has not consistently reduced hip fractures) — judged over years by fracture incidence.
- Control of Paget disease / hypercalcemia of malignancy
- Restraining overactive osteoclasts normalizes the accelerated turnover of Paget disease (falling alkaline phosphatase) and lowers the serum calcium driven by bone-destroying malignancy (IV agents).
Adverse effects
The common problem is upper-GI/esophageal irritation, prevented by the protocol; the serious ones are ONJ, atypical femoral fracture, hypocalcemia, and (IV) the acute-phase reaction and renal toxicity. No class-wide boxed warning.
Interactions
Contraindications
The oral contraindications are about the protocol (esophageal anatomy, staying upright). Hypocalcemia is also a labeled contraindication for the oral agents and for zoledronic acid 5 mg (Reclast), which is also contraindicated in significant or acute renal impairment. The oncology IV products (zoledronic acid 4 mg, pamidronate) list only hypersensitivity as a contraindication; for them, correcting hypocalcemia and avoiding use in severe renal impairment are warnings.
When to hold
Assess before giving — these findings mean hold the dose and act.
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are Bisphosphonates used for?
How do Bisphosphonates work?
What are the serious side effects of Bisphosphonates?
When should a nurse hold Bisphosphonates, and what safety checks apply?
Conditions treated
Adjuvant bone-modifying therapy — role uncertain. "Both bisphosphonates and denosumab have been evaluated as adjuvant therapies for early-stage breast cancer; however, their role is unclear."
Bone protection and hypercalcemia. "Most patients also receive a bisphosphonate or RANKL inhibitor to prevent skeletal-related complications" — given IV monthly. Class warnings: osteonecrosis of the jaw (dental exam first), renal monitoring (creatinine before each dose), hypocalcemia (an oral calcium supplement is advised), and severe bone, joint or muscle pain. Denosumab (no class page) is an alternative "especially when renal dysfunction precludes the use of bisphosphonates."
The definitive medical therapy for hypercalcemia of malignancy: they shut down the osteoclast-mediated bone resorption that PTHrP and lytic metastases drive. Onset is 2–3 days with an effect lasting 2–4 weeks — zoledronic acid preferred over pamidronate — so calcitonin bridges the gap (works in hours, wears off within days). Denosumab, a RANKL inhibitor useful in renal impairment, is now recommended early — per Endocrine Society guidance as relayed by StatPearls, some sources call it first-line.
The default drug for osteoporosis — "the most commonly used therapeutic agents prescribed," and the first-line choice for anyone not at very high risk, with intravenous dosing when oral is contraindicated and denosumab as the alternative when bisphosphonates cannot be used, such as in renal failure. They bind hydroxyapatite at remodeling sites and shut down the osteoclast: nitrogen-containing agents inhibit farnesyl pyrophosphate synthase so the osteoclast detaches from bone, while non-nitrogen agents form a nonfunctional ATP analogue that triggers osteoclast apoptosis. The administration rules exist because oral absorption is under 3% even fasting — take it first thing in the morning, on an empty stomach, with a full glass of plain water, and stay upright for at least 30 minutes (30 to 60 per the osteoporosis chapter) before food or any other medication. Three disorder-specific safety points: correct vitamin D and calcium before the first dose, because hypocalcemia is the risk; obtain a dental examination first, because of osteonecrosis of the jaw; and know the renal floor — risedronate and ibandronate are not used below a GFR of 30 mL/min, alendronate and zoledronic acid below 35. Not every agent covers every fracture: alendronate, risedronate and zoledronate reduce vertebral, hip and nonvertebral fractures, but ibandronate reduces vertebral fractures only. Concomitant NSAIDs raise the gastrointestinal risk, and gastrointestinal effects are the commonest reason patients stop.
Slow but lasting for hypercalcemia of malignancy — and a cause of low calcium. "Both pamidronate and zoledronic acid are approved for treating hypercalcemia of malignancy," and they "typically take approximately 3 days to lower calcium levels back to the normal range," with effects lasting weeks. "The main adverse effects of bisphosphonates include osteonecrosis of the jaw and nephrotoxicity." In non-operated primary hyperparathyroidism, alendronate raises bone density but does not normalise calcium. Because they inhibit bone resorption, bisphosphonates "may lower serum calcium" — a drug cause of hypocalcemia.
Men on antiandrogen therapy or after orchiectomy lose bone — "bisphosphonate drugs lessen the risk of bone fracture"; they also reduce bone disease when prostate cancer has spread to bone.
See also
Block cyclooxygenase to relieve pain, inflammation, and fever — at the price of GI bleeding, cardiovascular, and renal risk. They carry a two-part boxed warning.
Ease muscle spasm and spasticity — mostly by sedating the CNS. The defining risks are drowsiness/falls and additive depression with opioids, benzodiazepines, and alcohol.
Beyond the bisphosphonates, three kinds of drug treat bone and calcium. Teriparatide, abaloparatide and romosozumab build bone. Denosumab, raloxifene and calcitonin slow bone loss in other ways. Cinacalcet and calcitriol reset the calcium–parathyroid balance. Serum calcium runs through the nursing care of nearly all of them, and three carry boxed warnings: denosumab (Prolia) for severe hypocalcemia in advanced kidney disease, romosozumab for heart attack and stroke, and raloxifene for blood clots and death from stroke.
Two different jobs: stop an acute attack vs lower uric acid long-term. Don’t stop urate-lowering therapy for a flare.
Sources
- Fosamax (alendronate) — administration rules, esophagitis warning, contraindications, ONJ & atypical fractures (FDA label) — FDA / DailyMed
- Bisphosphonates — FPPS mechanism, indications, adverse effects & drug holiday — StatPearls (NCBI)
- Ibandronate tablets — 60-minute upright rule, plain-water & separation instructions (FDA label) — FDA / DailyMed
- ACTONEL (risedronate) — administration, contraindications, 3–5-year duration (FDA label) — FDA / DailyMed
- ATELVIA (risedronate delayed-release) — contraindications, ocular inflammation (FDA label) — FDA / DailyMed
- RECLAST (zoledronic acid) — renal contraindication (CrCl <35), hydration, acute-phase reaction, oral exam (FDA label, current Sandoz SPL) — FDA / DailyMed
- Pamidronate Disodium Injection — hypercalcemia of malignancy, dental exam before treatment (FDA label) — FDA / DailyMed
- Osteoporosis in Females — bone remodeling, peak bone mass, WHO definition, DEXA T-score and treatment monitoring — StatPearls (NCBI)
- The use of stems in the selection of INN for pharmaceutical substances (2018) — -dronic acid (USAN -dronate) — World Health Organization
- Drugs@FDA — ZOMETA and AREDIA marketing status — FDA (openFDA)
- Zoledronic acid injection 4 mg (oncology; Zometa-equivalent) — contraindications, renal and hypocalcemia warnings, oral-symptom counseling (FDA label) — FDA / DailyMed
- Alendronate sodium oral solution — do not give with increased aspiration risk (FDA label) — DailyMed (NLM)
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.